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BACKGROUND
Uterine fibroids, the most common type of tumor among women of reproductive 
age, are associated with heavy menstrual bleeding, abdominal discomfort, subfer-
tility, and a reduced quality of life. For women who wish to preserve their uterus 
and who have not had a response to medical treatment, myomectomy and uterine-
artery embolization are therapeutic options.
METHODS
We conducted a multicenter, randomized, open-label trial to evaluate myomectomy, 
as compared with uterine-artery embolization, in women who had symptomatic 
uterine fibroids and did not want to undergo hysterectomy. Procedural options 
included open abdominal, laparoscopic, or hysteroscopic myomectomy. The primary 
outcome was fibroid-related quality of life, as assessed by the score on the health-
related quality-of-life domain of the Uterine Fibroid Symptom and Quality of Life 
(UFS-QOL) questionnaire (scores range from 0 to 100, with higher scores indi-
cating a better quality of life) at 2 years; adjustment was made for the baseline 
score.
RESULTS
A total of 254 women, recruited at 29 hospitals in the United Kingdom, were ran-
domly assigned: 127 to the myomectomy group (of whom 105 underwent myomec-
tomy) and 127 to the uterine-artery embolization group (of whom 98 underwent 
embolization). Data on the primary outcome were available for 206 women (81%). 
In the intention-to-treat analysis, the mean (±SD) score on the health-related 
quality-of-life domain of the UFS-QOL questionnaire at 2 years was 84.6±21.5 in 
the myomectomy group and 80.0±22.0 in the uterine-artery embolization group 
(mean adjusted difference with complete case analysis, 8.0 points; 95% confidence 
interval [CI], 1.8 to 14.1; P = 0.01; mean adjusted difference with missing respons-
es imputed, 6.5 points; 95% CI, 1.1 to 11.9). Perioperative and postoperative com-
plications from all initial procedures, irrespective of adherence to the assigned 
procedure, occurred in 29% of the women in the myomectomy group and in 24% 
of the women in the uterine-artery embolization group.
CONCLUSIONS
Among women with symptomatic uterine fibroids, those who underwent myomec-
tomy had a better fibroid-related quality of life at 2 years than those who under-
went uterine-artery embolization. (Funded by the National Institute for Health 
Research Health Technology Assessment program; FEMME Current Controlled 
Trials number, ISRCTN70772394.)
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The prevalence of uterine fibroids, the most common type of tumor among women of reproductive age, increases with 
age.1-3 Approximately half of women with fibroids 
have bothersome symptoms, including heavy 
menstrual bleeding, abdominal pain, and pres-
sure,3 that negatively affect quality of life.4,5 
Submucosal fibroids and, to a lesser extent, 
intramural fibroids have been associated with 
subfertility and adverse pregnancy outcomes,6,7 
although data are inconsistent.8
Surgery, either myomectomy or hysterectomy, 
has traditionally been the primary approach for 
the management of symptomatic fibroids; uterine-
artery embolization emerged as an alternative 
during the 1990s. Myomectomy involves the 
surgical removal of the fibroid and preservation 
of the uterus. Although myomectomy substan-
tially reduces heavy bleeding, it is associated with 
myometrial trauma, and whether it results in 
improved reproductive outcomes is not known.9
Uterine-artery embolization, which is usually 
performed while the patient is under local anes-
thesia, involves temporary occlusion of the arter-
ies supplying the uterus, with the use of biocom-
patible particles, to cause ischemic infarction 
of the fibroids. As compared with myomectomy, 
uterine-artery embolization is associated with a 
shorter hospital stay and an earlier return to 
normal activities10,11 but also a higher likelihood 
of the need for additional intervention.12 Con-
cern regarding a possible effect on ovarian and 
uterine function has resulted in recommenda-
tions against the use of uterine-artery emboliza-
tion in women who plan to become pregnant; 
however, the results of a recent meta-analysis 
suggested no appreciable effect on ovarian re-
serve.13
Observational studies have shown sustained 
improvements in quality of life, as measured with 
the use of the validated Uterine Fibroid Symp-
tom and Quality of Life (UFS-QOL) question-
naire,14-17 at 3 to 5 years after myomectomy18 or 
uterine-artery embolization,19 but long-term out-
come data to directly compare these procedures 
are limited.20 In two randomized trials comparing 
uterine-artery embolization with myomectomy10,11,14 
in which data from a total of 243 women were 
analyzed, myomectomy was associated with a 
greater improvement in quality of life and better 
reproductive outcomes than uterine-artery em-
bolization; however, there was substantial attri-
tion in one trial (the FUME [Fibroids of the 
Uterus: Myomectomy versus Embolization] trial),11 
and in both trials, complete follow-up occurred 
only through 1 year after randomization.11,14 Two 
other randomized trials compared uterine-artery 
embolization with hysterectomy or myomecto-
my.21,22 A meta-analysis that assessed rates of 
patient satisfaction after 2 years yielded incon-
clusive results, which underscores the need for 
more comparative evidence.12 We conducted the 
FEMME trial (A Randomized Trial of Treating 
Fibroids with Either Embolisation or Myomec-
tomy to Measure the Effect on Quality of Life 
Among Women Wishing to Avoid Hysterectomy), 
a multicenter, randomized trial to evaluate myo-
mectomy, as compared with uterine-artery em-
bolization, in women who had symptomatic 
uterine fibroids and did not want to undergo 
hysterectomy.
Me thods
Trial Design and Oversight
Details of the design of the FEMME trial have 
been published previously.23 The full trial proto-
col and statistical analysis plan are available with 
the full text of this article at NEJM.org.
The FEMME trial was approved by the United 
Kingdom National Research Ethics Service and 
the research department at each participating 
hospital. Trial oversight and monitoring were 
provided by a trial steering committee and by an 
independent data and safety monitoring commit-
tee, whose members reviewed accruing safety 
data during the period of recruitment. The sixth, 
seventh, penultimate, and last author vouch for 
the accuracy and completeness of the data and 
for the fidelity of the trial to the protocol.
Trial Participants
The participants were recruited at 29 hospitals 
in the United Kingdom. Women were eligible for 
enrollment in the trial if they were older than 18 
years of age, were premenopausal, were not preg-
nant, and had symptomatic fibroids that could 
be treated with myomectomy or uterine-artery 
embolization. Women were excluded if they had 
substantial adenomyosis, had a suspected or diag-
nosed cancer, had recent or ongoing pelvic in-
flammatory disease, or had undergone a previous 
open abdominal myomectomy or uterine-artery 
embolization. All the participants provided writ-
ten informed consent.
The diagnosis and characterization of uterine 
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fibroids involved history taking, pelvic examina-
tion, and ultrasonography, usually followed by 
magnetic resonance imaging (MRI) with contrast 
enhancement, to facilitate planning of the pro-
cedure. A gynecologist determined whether the 
fibroid could be treated with open abdominal or 
laparoscopic removal, and an interventional 
radiologist considered whether uterine-artery 
embolization was feasible. Women were eligible 
to participate in the trial only if they were con-
sidered to be eligible for both procedures.
Trial Assignments and Procedures
Participants were randomly assigned, in a 1:1 
ratio, to undergo myomectomy or uterine-artery 
embolization as the primary procedure. Owing to 
the nature of the procedures, blinding was not 
considered to be feasible. Computerized random-
ization was performed centrally through a secure 
Internet facility with the use of minimization to 
balance the treatment-group assignments accord-
ing to the longest dimension of the largest fi-
broid (≤7 cm vs. >7 cm), the number of fibroids 
(1 to 3 vs. 4 to 10 vs. >10), and whether the 
woman wanted to become pregnant (yes vs. no).
Bilateral selective catheterization and emboli-
zation of the uterine arteries were performed 
under fluoroscopic guidance. The specific em-
bolic agent used was at the discretion of the inter-
ventional radiologist, and the end point of the 
embolization procedure was complete or near-
complete stasis of blood flow in the uterine artery.
Myomectomy was performed by the route pre-
ferred by the operating gynecologist (open ab-
dominal, hysteroscopic, laparoscopic, or a com-
bination of these). A gonadotropin-releasing 
hormone analogue or ulipristal acetate was ad-
ministered before the procedure if it was deemed 
by the gynecologist to be essential. Concurrent 
procedures such as adhesiolysis were not re-
stricted.
Outcome Measures
The primary outcome was the score on the health-
related quality-of-life domain of the UFS-QOL 
questionnaire (scores range from 0 to 100, with 
higher scores indicating a better quality of life) 
at 2 years after randomization. The instrument 
has face, construct, and discrimination validity 
and has been shown to be responsive to change.15-17
Prespecified quality-of-life secondary outcomes 
were the following: the score on the health-related 
quality-of-life domain of the UFS-QOL question-
naire at 6 months and at 1 year, the score on the 
symptom severity domain of the UFS-QOL ques-
tionnaire (scores range from 0 to 100, with 
higher scores indicating increased severity), the 
score on the European Quality of Life 5-Dimen-
sion 3-Level (EQ-5D-3L) questionnaire (scores 
range from −0.59 to 1.00, with higher scores 
indicating a better quality of life),24 and the 
score on the EQ-5D visual analogue scale (scores 
range from 0 [indicating the worst possible 
health state] to 100 [indicating the best possible 
health state]).
Women estimated menstrual blood loss (the 
number of sanitary napkins or tampons used 
and the extent of soiling with blood) with the 
use of the pictorial blood-loss assessment chart 
and recorded their estimates in diary entries. 
Scores were then generated from the diary en-
tries, with 0 as the lowest score (indicating no 
bleeding) and higher scores (no defined upper 
limit) indicating more bleeding. This measure 
was also used to generate rates of amenorrhea 
and of nonheavy bleeding (defined as a score 
<100).25 Participants were free to choose the 
brand of sanitary protection they preferred and 
to use any pharmacologic cointerventions.
Other secondary outcomes were the occur-
rence of pregnancy (overall and among partici-
pants who had indicated at the time of random-
ization that they wanted to become pregnant), a 
pregnancy outcome (live birth, miscarriage, still-
birth, or termination), participant satisfaction 
(determined on the basis of responses to “would 
you have your operation again?” and “would you 
recommend the operation to a friend?”), the 
length of hospital stay, and the occurrence of 
additional fibroid-related procedures. Each par-
ticipant-completed outcome assessment was col-
lected at 6 months, 1 year, and 2 years after 
randomization. Ovarian reserve was determined 
on the basis of blood levels of follicle-stimulat-
ing hormone (FSH), antimüllerian hormone, and 
luteinizing hormone measured before myomec-
tomy or uterine-artery embolization was per-
formed and at 6 weeks, 6 months, and 1 year 
after the procedure; levels of FSH and luteinizing 
hormone were measured only if the blood sam-
ple was obtained on days 2 to 4 of the men-
strual cycle. Adverse events were elicited during 
three time windows: the time from the proce-
dure to hospital discharge, the time from dis-
charge to the 6-month postoperative visit, and 
the time from the 6-month postoperative visit to 
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the end of the trial, during which only serious 
adverse events, which included adverse events 
that were fatal, life-threatening, or resulted in 
hospitalization, were reported.
Statistical Analysis
The original sample size was 650 participants, 
which would have provided the trial with 90% 
power (at a two-sided alpha level of 0.05) to detect 
a small-to-moderate difference of 8 points (0.29 
of a standard deviation) in the score on the health-
related quality-of-life domain of the UFS-QOL 
questionnaire for the comparison of myomec-
tomy with uterine-artery embolization at 2 years; 
this sample size would have allowed for an ap-
proximately 20% loss of primary outcome data. 
The target difference between the groups was 
considered to be plausible on the basis of the 
results of the FUME trial.11 The establishment of 
a validated minimally important difference is 
lacking with respect to UFS-QOL score,16 as well 
as the secondary outcomes other than the EQ-5D 
score, for which a mean minimally important 
difference of 0.07 was derived from a review of 
11 varied patient populations.26
Because enrollment in the trial was progress-
ing more slowly than anticipated, and with ac-
cess to individual participant UFS-QOL data from 
the FUME trial, the sample size target was re-
vised to 250 participants in October 2013; at that 
time, 114 women had undergone randomiza-
tion. A reanalysis of data from the earlier trial,11 
in which more appropriate regression methods 
that accounted for baseline imbalances were 
used, suggested that a larger difference of 12 
points in the score on the health-related quality-
of-life domain of the UFS-QOL questionnaire 
was attainable and that the pooled-group stan-
dard deviation of UFS-QOL scores was slightly 
lower than originally estimated. The revised 
sample size of 250 participants provided 90% 
power to detect a moderate-sized difference be-
tween the groups (0.55 of a standard deviation).
The analysis of the primary outcome was 
performed according to the intention-to-treat 
principle; the main analysis included all observed 
data (the complete case analysis), and a sensitiv-
ity analysis, which included data from all par-
ticipants who underwent randomization, took 
into account any missing responses with the use 
of multiple imputation. A linear regression model 
for repeated measures27 that included data at all 
time points was used to estimate least-squares 
mean differences between the groups (with cor-
responding two-sided 95% confidence intervals) 
in the primary outcome at 2 years. The model 
included participant, treatment group, baseline 
score, time, interaction between time and treat-
ment group, and the minimization variables. 
Participants were included in the complete case 
analysis if they had at least one response at any 
of the three assessment time points. In the 
analysis that took missing responses into ac-
count, multiple imputation was performed with 
the use of the Markov chain Monte Carlo method, 
which assumed a joint multivariate normal dis-
tribution. The imputation model was consistent 
with the analysis model.28
For the primary outcome, a P value was gen-
erated with the use of the aforementioned linear 
regression model. The statistical analysis plan 
did not include a provision for correction for 
multiple comparisons when the analyses of the 
secondary effectiveness outcomes were performed. 
Therefore, the results are reported as point esti-
mates and 95% confidence intervals, without 
P values. Observed data for secondary continu-
ous outcomes were analyzed in a manner similar 
to that used for the primary outcome; reproduc-
tive hormone levels were log-transformed and 
hence are presented as the ratio of geometric 
means for ease of interpretation. Log-binomial 
regression was used to estimate relative rates 
and 95% confidence intervals for binary out-
comes, with adjustments similar to those used 
in the other analyses. The widths of the confi-
dence intervals were not adjusted for multiple 
comparisons, so the intervals should not be used 
to infer definitive treatment effects.
Several sensitivity analyses of the primary 
outcome were performed, including an analysis 
in which time was included as a continuous lin-
ear predictor, under the assumption of no inter-
action with treatment; an analysis in which a 
variable for treating hospital was added; and a 
per-protocol analysis that included only partici-
pants who underwent the procedure to which 
they had been assigned. Because some question-
naires were incomplete, we performed an addi-
tional sensitivity analysis using available subscale 
scores to generate an overall score.
We analyzed the treatment effect on the pri-
mary outcome in prespecified subgroups that 
matched the minimization variables (the size of 
the largest fibroid, the number of fibroids, and 
whether the participant wanted to become preg-
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nant). The effects of these subgroups were ex-
amined by adding the variable for the interaction 
of subgroup with treatment group to the linear 
regression model. All analyses were performed 




Between February 6, 2012, and May 21, 2015, a 
total of 254 eligible women provided consent to 
participate and were randomly assigned to un-
dergo either myomectomy or uterine-artery em-
bolization (127 women in each group). The per-
centage of women with available data for the 
primary outcome at 2 years was 81% (206 of 254 
women) (Fig. 1); scores on the health-related 
quality-of-life domain of the UFS-QOL question-
naire were available at one or more assessment 
time points for 227 women (89%). Baseline char-
acteristics of the two groups were similar, and 
imaging results suggested similar severity and 
distribution of fibroids in the two groups (Ta-
ble 1). Adherence to the assigned treatment is 
shown in Figure 1 and in Figure S1 in the Sup-
plementary Appendix, available at NEJM.org. 
Timing and other details regarding myomecto-
my and uterine-artery embolization are provided 
in Table S1. Among the initial procedures per-
formed in the myomectomy group, 86 (82%) were 
open abdominal procedures.
Primary Outcome
The mean scores on the health-related quality-
of-life domain of the UFS-QOL questionnaire at 
2 years were substantially higher than the base-
line scores in both groups, but the magnitude of 
improvement was greater in the myomectomy 
group than in the uterine-artery embolization 
group (mean adjusted difference with complete 
case analysis, 8.0 points; 95% confidence inter-
val [CI], 1.8 to 14.1; P = 0.01; mean adjusted dif-
ference with missing responses imputed, 6.5 
points; 95% CI, 1.1 to 11.9) (Table 2, Fig. 2, and 
Table S2). Other sensitivity analyses yielded 
similar results. The results of the prespecified 
subgroup analysis are provided in Table S3.
Secondary Outcomes
The mean score on the health-related quality-of-
life domain was also higher after myomectomy 
than after uterine-artery embolization at both 
6 months and 1 year (Table 2 and Fig. 2). The 
mean differences in the UFS-QOL symptom se-
verity domain were −6.1 points (95% CI, −11.4 to 
−0.9), favoring myomectomy, at 6 months and 
−3.8 (95% CI, −9.4 to 1.8), favoring myomectomy, 
at 2 years, whereas menstrual bleeding scores 
appeared similar in the two groups (Table S4). 
At 2 years, the percentage of women who indi-
cated that they would recommend a given proce-
dure to a friend was 93% in the myomectomy 
group, as compared with 84% in the uterine-
artery embolization group, whereas the percent-
ages of women who indicated that they would be 
willing to undergo the procedure again were 
78% and 74%, respectively (Table S5).
In total, 9 women (8%) in the uterine-artery 
embolization group and 5 women (4%) in the 
myomectomy group reported a pregnancy with-
in 2 years after randomization; there were 6 live 
births in the uterine-artery embolization group 
and 4 live births in the myomectomy group. The 
hormonal levels did not appear to be materially 
different in the two groups at the majority of 
time points (Tables S6 and S7).
The incidence of intraoperative complications 
was low, with only one conversion of a myomec-
tomy to a hysterectomy and one conversion of a 
laparoscopic myomectomy to an open abdominal 
myomectomy. At 6 months after uterine-artery 
embolization, 32 of 80 (40%) of the fibroids 
treated, for which repeat MRI was performed, 
were completely infarcted. The results of the 
intention-to-treat analysis of procedural compli-
cations are shown in Table 3, and the results of 
the per-protocol analysis (which included only 
participants who underwent the procedure to 
which they had been assigned) are provided in 
Table S8. Perioperative and postoperative com-
plications from all initial procedures occurred in 
27 of 113 women (24%) in the uterine-artery 
embolization group and in 34 of 118 women 
(29%) in the myomectomy group (relative risk, 
1.2; 95% CI, 0.8 to 1.9; P = 0.40). The median 
length of hospital stay was 2 days (interquartile 
range, 2 to 3) for the uterine-artery embolization 
group and 4 days (interquartile range, 3 to 5) 
for the myomectomy group. Among the 110 
women in the uterine-artery embolization group 
and 111 women in the myomectomy group for 
whom data were available at 2 years, additional 
fibroid-related procedures were performed in 
18 women (16%) and 8 women (7%), respectively 
(Table S9).
n engl j med 383;5 nejm.org July 30, 2020 445
Uterine-Artery Embolization or Myomectomy for Fibroids
Discussion
Although improvement in participant-reported 
health-related quality-of-life scores was observed 
after both myomectomy and uterine-artery embo-
lization at 2 years, the scores indicated a higher 
health-related quality of life among women as-
signed to undergo myomectomy. Menstrual bleed-
ing scores appeared similar in the two groups. 
The overall incidence of complications associat-
ed with both procedures was low. Additional pro-
cedures were performed in 7% of the women in 
the myomectomy group, as compared with 16% 
in the uterine-artery embolization group; the 
median length of hospital stay was 4 days with 
myomectomy and 2 days with uterine-artery 
embolization.
The 6-to-8-point benefit, on average, in health-
Figure 1. Randomization, Treatment, and Follow-up.
All mentions of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire refer to the health-related 
quality-of-life portion of the questionnaire. Participants were deemed lost to follow-up only if they did not complete 
the UFS-QOL questionnaire at 2 years. Participants who did not complete the questionnaire at 6 months or at 1 year 
but subsequently completed the questionnaire at 2 years were not considered to be lost to follow-up.
254 Women underwent randomization
127 Were assigned to undergo
uterine-artery embolization
127 Were assigned to undergo
myomectomy
3 Were withdrawn
2 Were lost to follow-up
4 Were withdrawn
113 Received intervention
98 (80%) Underwent uterine-artery
embolization
14 (11%) Underwent myomectomy
1 (1%) Underwent endometrial ablation
9 Did not receive intervention
119 Received intervention
105 (85%) Underwent myomectomy
6 (5%) Underwent uterine-artery
embolization
8 (7%) Underwent hysterectomy
4 Did not receive intervention
1 Was withdrawn
18 Were lost to follow-up
3 Were withdrawn
11 Were lost to follow-up
99 Completed UFS-QOL questionnaire at 6 mo
28 Had missing responses imputed
95 Completed UFS-QOL questionnaire at 6 mo
32 Had missing responses imputed
2 Were withdrawn 1 Was withdrawn
94 Completed UFS-QOL questionnaire at 1 yr
33 Had missing responses imputed
94 Completed UFS-QOL questionnaire at 1 yr
33 Had missing responses imputed
1 Was withdrawn 2 Were withdrawn
100 Completed UFS-QOL questionnaire
at 2 yr for primary outcome
27 Had missing responses imputed
113 Completed UFS-QOL questionnaire
at any time point
14 Did not complete UFS-QOL questionnaire
at any time point
106 Completed UFS-QOL questionnaire
at 2 yr for primary outcome
21 Had missing responses imputed
114 Completed UFS-QOL questionnaire
at any time point
13 Did not complete UFS-QOL questionnaire
at any time point
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Demographic characteristics and pregnancy history
Age — yr 40.2±6.55 42.7±6.4
Race or ethnic group — no. (%)†
White 59 (46) 57 (45)
Black 48 (38) 54 (43)
South Asian 10 (8) 5 (4)
Mixed 6 (5) 8 (6)
Other 4 (3) 3 (2)
Body-mass index‡
Mean 28.2±6.2 28.1±5.3
Data missing — no. (%) 8 (6) 4 (3)
Desire for pregnancy, at time of randomization — no. (%)§ 61 (48) 61 (48)
Parity
Median (IQR) 0 (0–1) 1 (0–2)
Data missing — no. (%) 2 (2) 0
Gravidity
Median (IQR) 1 (0–2) 2 (0–3)
Data missing — no. (%) 2 (2) 0
Fibroid assessment
Imaging used to diagnose fibroid — no. (%)¶
Magnetic resonance imaging 89 (70) 99 (78)
Ultrasonography 36 (28) 27 (21)
Data missing 2 (2) 1 (1)
Location of largest fibroid — no. (%)
Submucosa 6 (5) 14 (11)
Submucosa, pedunculated 1 (1) 1 (1)
Subserosa 30 (24) 21 (17)
Subserosa, pedunculated 6 (5) 5 (4)
Muscle wall‖ 74 (58) 81 (64)
Other 4 (3) 0
Data missing 6 (5) 5 (4)
Longest dimension of largest fibroid§
Distribution — no. (%)
≤7 cm 64 (50) 64 (50)
>7 cm 63 (50) 63 (50)
Mean — cm 7.6±3.2 7.7±4.2
No. of fibroids§
1–3 — no. (%) 84 (66) 84 (66)
4–10 — no. (%) 37 (29) 37 (29)
>10 — no. (%) 6 (5) 6 (5)
Median (IQR) 2 (1–5) 2 (1–5)
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related quality-of-life scores in the myomectomy 
group, as compared with the uterine-artery 
embolization group, is consistent with a small-
to-moderate standardized treatment benefit at 
2 years.29 However, the 95% confidence interval 
around these estimates indicates that plausible 
results can range from almost no benefit of 
myomectomy over embolization to a moderate 
(15-point) difference. Previous studies of these 
two interventions have shown similarly large 
improvements from baseline.11,20 The observed 
between-group difference in the EQ-5D score in 
the current trial is consistent with the reported 
mean minimally important difference in that 
scale26 and supports the between-group differ-
ence observed in the UFS-QOL score.
The substantially higher number of surgical 
reinterventions in the uterine-artery embolization 
group than in the myomectomy group during 
2 years of follow-up may be explained in part by 
the lower quality of life reported in the uterine-
artery embolization group. However, more hyster-
ectomies were performed as the initial proce-
dure in the myomectomy group than in the 
uterine-artery embolization group, owing either 
to patient preference or to clinical decision.
There were no consistent differences between 
the groups in the levels of biomarkers of ovarian 
reserve, assessed as continuous variables, even 
after adjustment for baseline values. Previous 
randomized trials, in which FSH levels were 
measured and varying thresholds for ovarian 
failure were used, also showed no convincing 
evidence of harm from uterine-artery emboliza-
tion.30 There were too few pregnancies in our 
trial to inform the effects of the procedures on 
fertility.
This trial was larger than previous trials that 
compared uterine-artery embolization with any 
surgery10,11,21,22 and provides information on 
patient-focused outcomes. Unlike trials of previ-
ous comparisons of myomectomy and uterine-
artery embolization, the current trial was a 








Mean — cm3 436±594 446±548
Data missing — no. (%) 3 (2) 1 (1)
Uterine volume
Mean — cm3 1170±1280 1240±1120
Data missing — no. (%) 9 (7) 9 (7)
Surgical and medication history
Previous abdominal surgery — no. (%)**
Cesarean section 12 (9) 19 (15)
Laparoscopy 19 (15) 15 (12)
Endometrial ablation 3 (2) 2 (2)
Appendectomy 8 (6) 7 (6)
Sterilization 4 (3) 5 (4)
Other 10 (8) 15 (12)
Contraceptive or hormonal treatments to control symptoms,  
at time of randomization — no. (%)
75 (59) 73 (57)
*  Plus–minus values are means ±SD. IQR denotes interquartile range.
†  Race or ethnic group was determined from hospital records.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  This variable was a minimization variable.
¶  A participant could have undergone more than one type of imaging procedure.
‖  This location is also referred to as “intramural.”
**  A participant could have undergone more than one type of abdominal surgery previously.
Table 1. (Continued.)
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UFS-QOL health-related quality-of-life domain score‡
Baseline§
No. of participants 116 119
Mean score 42.1±26.4 37.0±23.9
6 mo§
No. of participants 99 95
Mean score 73.9±26.7 80.5±21.7 7.4 (0.5 to 14.2)
1 yr§
No. of participants 94 94
Mean score 75.7±26.1 84.7±22.1 10.8 (4.2 to 17.5)
2 yr, the time point of the primary outcome
No. of participants 100 106
Mean score 80.0±22.0 84.6±21.5 8.0 (1.8 to 14.1)
UFS-QOL symptom severity domain score¶
Baseline
No. of participants 122 125
Mean score 58.5±26.0 59.4±21.0
6 mo
No. of participants 100 97
Mean score 27.3±21.2 21.6±17.1 −6.1 (−11.4 to −0.9)
1 yr
No. of participants 95 96
Mean score 25.7±21.5 20.4±19.0 −5.4 (−11.0 to 0.2)
2 yr
No. of participants 100 106
Mean score 21.9±20.8 19.5±20.0 −3.8 (−9.4 to 1.8)
EQ-5D-3L score‖
Baseline
No. of participants 125 127
Mean score 0.62±0.34 0.63±0.32
6 mo
No. of participants 100 98
Mean score 0.77±0.30 0.85±0.17 0.09 (0.03 to 0.14)
1 yr
No. of participants 98 98
Mean score 0.77±0.30 0.85±0.23 0.08 (0.01 to 0.15)
2 yr
No. of participants 99 106
Mean score 0.80±0.29 0.88±0.20 0.07 (0.01 to 0.13)
EQ-5D visual analogue scale score**
Baseline
No. of participants 125 127
Mean score 62.9±23.8 62.7±23.2
n engl j med 383;5 nejm.org July 30, 2020 449











No. of participants 98 100
Mean score 74.2±20.9 79.7±15.7 5.7 (1.1 to 10.3)
1 yr
No. of participants 98 97
Mean score 74.4±21.1 81.3±15.3 7.0 (2.1 to 11.9)
2 yr
No. of participants 101 106
Mean score 74.7±19.4 80.8±14.7 6.1 (1.7 to 10.6)
*  Plus–minus values are means ±SD. The number of participants listed at each time point represents the total number 
of participants who had a fully completed questionnaire at that time point. EQ-5D denotes European Quality of Life 
5-Dimension, EQ-5D-3L European Quality of Life 5-Dimension 3-Level, and UFS-QOL Uterine Fibroid Symptom and 
Quality of Life.
†  Least-squares mean differences were estimated with the use of a regression model; estimates were adjusted for base-
line value and minimization variables.
‡  Scores range from 0 to 100, with higher scores indicating a better quality of life. A mean difference of greater than 
zero favors myomectomy.
§  Additional participants returned partially complete questionnaires (17 participants at baseline, 6 at 6 months, and 5 at 
1 year); available subscale scores were used in the sensitivity analysis.
¶  Scores range from 0 to 100, with higher scores indicating increased severity. A mean difference of less than zero favors 
myomectomy.
‖  Scores range from −0.59 to 1.00, with higher scores indicating a better quality of life. A mean difference of greater 
than zero favors myomectomy.
**  Scores range from 0 (indicating the worst possible health state) to 100 (indicating the best possible health state).  
A mean difference of greater than zero favors myomectomy.
Table 2. (Continued.)
Figure 2. Mean UFS-QOL Health-Related Quality-of-Life Scores over Time, According to Treatment Group.
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from regression model after




Uterine-artery embolization, least-squares 
mean from regression model after
imputation of missing values
Uterine-artery embolization, least-squares 
mean from regression model
Uterine-artery embolization, observed mean
Estimated least-squares mean difference at 2 yr,
8.0 points (95% CI, 1.8–14.1); with missing
responses imputed, 6.5 points (95% CI, 1.1–11.9)
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women on the basis of their intentions with re-
gard to pregnancy. The generalizability of the 
findings is increased by the inclusion of multiple 
centers, surgeons, and interventional radiolo-
gists, as well as a substantial number of partici-
pants of African and Caribbean descent. The 
incidence of procedural complications was low 
in both groups, perhaps reflecting the expertise 
in the participating centers.
Our trial had some limitations. First, 19% of 
the participants did not return the primary out-
come questionnaire at 2 years. Our analytic ap-
proach involved imputation of missing responses 
with the use of a recognized method but as-
sumed that data were missing at random. Any 
deviation from this assumption could give rise 
to inconclusive results, given that the lower end 
of our confidence intervals around the effect 
estimates were close to zero. Second, a number 
of participants did not receive the intervention to 
which they were randomly assigned; however, 
this occurred at similar frequency in both groups, 
and the results were not materially different in 
the per-protocol analysis. Third, despite random-
ization, some baseline differences between the 
groups were noted in health-related quality of 
life and age. However, prespecified analyses 
were adjusted for the baseline health-related 
quality-of-life score, and a post hoc analysis with 
adjustment for age showed similar findings. 
Fourth, a substantial amount of data on FSH and 
luteinizing hormone levels was missing, since 
many blood samples were not obtained within 
the specified time frame. Fifth, many women 
declined to participate in the trial owing to hav-
ing a preference for a particular treatment op-
tion. Finally, the lack of blinding may have af-
fected the reporting of subjective outcomes.
In conclusion, this multicenter trial showed 
the superiority of myomectomy over uterine-
artery embolization with respect to health-related 
quality of life. The overall incidence of peri-
operative and postoperative complications was 
similar in the two groups.
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no. of participants/total no. (%)
Perioperative or predischarge complica-
tions*
Access-artery occlusion 1/113 (1) 0
Postembolization syndrome resulting 
in a delay in discharge†
2/113 (2) 0
Hematoma 0 3/118 (3)
Major hemorrhage 2/113 (2) 6/118 (5)
Blood transfusion 4/113 (4) 11/118 (9)
Infection 0 5/118 (4)
Other‡ 1/113 (1) 3/118 (3)
Postdischarge complications§
Access-artery occlusion 1/109 (1) 0
Postembolization syndrome resulting 
in readmission
3/109 (3) 0
Hematoma 0 2/114 (2)
Infection 15/109 (14) 17/114 (15)
Other¶ 10/109 (9) 8/114 (7)
*  Complications occurred in 27 of 113 participants (24%) in the uterine-artery 
embolization group and in 34 of 118 participants (29%) in the myomectomy 
group (relative risk, 1.2; 95% CI, 0.8 to 1.9; P = 0.40).
†  Postembolization syndrome is characterized clinically by low-grade fever, pain, 
fatigue, nausea, and vomiting, typically within 48 hours after uterine-artery 
embolization, and symptoms usually resolve within a week.
‡  The complication in the uterine-artery embolization group was an episode of 
hypotension while the participant was in recovery after surgery. The complica-
tions in the myomectomy group were persistent oozing, resulting in ligation 
of the internal iliac vessels; constipation; and anesthesia awareness.
§  Postdischarge complications were recorded from the time of discharge from 
the hospital to 6 weeks after discharge.
¶  The complications listed here relate to 1 participant, unless otherwise speci-
fied. The complications in the uterine-artery embolization group were anemia 
(2 participants), sciatica, constipation, atypical cells found during the histo-
logic examination of the fibroid, pain in the left upper thigh, fibroid expulsion, 
suspected infection, and readmission because of pain (2 participants). The 
complications in the myomectomy group were norovirus; abdominal pain; 
bleeding in the upper gastrointestinal tract, with Helicobacter pylori infection; 
chest pain, dyspnea, and tachycardia; a gaping wound, with leakage (2 partici-
pants); leiomyosarcoma; and constipation.
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